DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Clinical trial NCT03358719 · COMPLETED

Trial details

NCT number: NCT03358719
Sponsor: Roswell Park Cancer Institute
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Blasts 30 Percent or Less of Bone Marrow Nucleated Cells Chronic Myelomonocytic Leukemia High Risk Myelodysplastic Syndrome Myelodysplastic Syndrome Refractory Anemia

Start date: 2018-03-27
Primary completion: 2020-02-27
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.